Remedium Bio, a pioneering genetic medicine company, has announced a strategic multi-target research and development collaboration with Eli Lilly and Company to advance gene therapies for Type 2 diabetes and obesity. The partnership will leverage Remedium's proprietary Prometheus™ dose-adjustable gene therapy platform to develop one-time treatments designed to offer tunable control of therapeutic protein expression with multi-year efficacy.
Revolutionary Gene Therapy Platform
The collaboration centers on Remedium's Prometheus™ platform, which enables safe, effective, and durable delivery of therapeutic genes while allowing for simple post-treatment dose adjustment. This subcutaneously administered gene delivery system aims to replace a broad range of protein-based treatments with a single injection at a fraction of the current therapeutic treatment cost.
"We are thrilled to collaborate with Lilly, a global leader in metabolic disease therapeutics, to bring durable, tunable therapies to patients living with Type 2 diabetes and obesity," said Frank Luppino, CEO of Remedium Bio. "This collaboration validates the potential of the Prometheus™ platform to transform the patient experience and expands its reach to one of the world's largest therapeutic markets."
Financial Terms and Strategic Value
Under the terms of the agreement, Remedium Bio will receive an upfront payment, equity investment, and potential development and commercialization milestone payments. The company is also eligible to receive tiered royalties on worldwide net sales of any resulting products developed through the collaboration.
The partnership represents a significant validation of Remedium's technology platform and its potential to address major unmet medical needs. Andrew Worden, Founding Partner at Lifespan Vision Ventures, which is an investor in Remedium, commented: "It is a powerful validation of their platform and is an important step toward developing interventions that extend healthspan."
Addressing Major Therapeutic Markets
The collaboration will focus on multiple targets for the treatment of obesity and Type 2 diabetes, leveraging Lilly's deep expertise in metabolic diseases. This approach has the potential to replace many protein-based treatments while offering patients safe, durable, and tunable control over therapeutic protein expression.
Remedium's pipeline includes several disease-modifying treatments with applications across endocrinology, immunology, neurology, and musculoskeletal diseases. The company's technology platform enables genetic medicine to address common conditions safely, effectively, and at scale.
Company Background and Location
Remedium Bio is based in Lilly Gateway Labs, Boston, which is part of the Lilly Catalyze360™ model. This comprehensive approach empowers early-stage biotech startups across all therapeutic areas by providing access to funding as well as world-class lab space and drug development talent and resources through its three pillars: Lilly Ventures, Lilly Gateway Labs®, and Lilly ExploR&D™.
The collaboration represents a significant milestone for Remedium as it scales its platform and translates it into therapies that can benefit millions of patients with metabolic diseases. The partnership aims to develop interventions that could meaningfully reshape the treatment landscape for conditions such as obesity and Type 2 diabetes.
